DelveInsight’s “Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Plaque Psoriasis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Plaque Psoriasis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Plaque Psoriasis: An Overview
Psoriasis generally refers to a common skin condition that speeds up the life cycle of skin cells. It causes cells to build up rapidly on the surface of the skin. The extra skin cells form scales and red patches that are itchy and sometimes painful.
Plaque psoriasis is a chronic autoimmune condition. It may be localized or widespread and accounts for most psoriasis cases. it is characterized by red patches of thickened skin (plaques) covered in silver scales. Any body area may be affected, but the main areas are the knees, elbows, lower back, and scalp.
Plaque Psoriasis Market Key Facts
According to National Psoriasis Foundation (NPF), more than 8 million Americans have psoriasis. Plaque psoriasis is the most common form of the disease, affecting ~80-90% of those with psoriasis.
In the United States, the prevalence of Psoriasis is estimated to be 0.6 to 4.81%. 125 million people worldwide, which is about 2 to 3 percent of the total population, have psoriasis, according to the World Psoriasis Day consortium.
According to the study published by Griffiths et al., the prevalence of psoriasis is estimated to be around 1.3-2.2% in the UK, with the greatest prevalence being in white people. Men and women are equally affected.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Plaque Psoriasis market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Plaque Psoriasis market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Plaque Psoriasis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Plaque Psoriasis Epidemiology Segmentation
Severity-Specific Prevalence of Plaque Psoriasis
Total Prevalence of Psoriasis
Total Prevalence of Plaque Psoriasis
Diagnosed and Treatable Cases of Plaque Psoriasis
Plaque Psoriasis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Plaque Psoriasis market or expected to get launched during the study period. The analysis covers Plaque Psoriasis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Plaque Psoriasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/plaque-psoriasis-market
Major Developments in the Plaque Psoriasis Therapeutics Market
• Amgen presented the results from a pair of phase 3 clinical trials of oral apremilast (Otezla) at EADV 2022 and revealed significant improvements in genital psoriasis in adults and severe plaque psoriasis in pediatric patients.
• On September 9, 2022, Bristol Myers Squibb announced that US FDA approved Sotyktu™(deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis. The approval is based on results from the pivotal phase 3 POETYK PSO-1 and POETYK PSO-2 multinational, multicenter, randomized, double-blind clinical trials.
Plaque Psoriasis Therapeutics Analysis
There are approx. 75+ key companies which are developing therapies for Plaque Psoriasis. Currently, Arcutis Biotherapeutics has its Plaque Psoriasis drug candidates in the most advanced stage (preregistration) of clinical development.
Some of the key companies in the Plaque Psoriasis Therapeutic Market include:
Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, and many others
Plaque Psoriasis Emerging Drugs
• ARQ-151: Arcutis Biotherapeutics
• ABY-035: Affibody
• AK101: Akeso Biopharma
And many others
Get More Detailed Insights Into the Emerging Therapies & Key Companies –
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Plaque Psoriasis Competitive Intelligence Analysis
4. Plaque Psoriasis Market Overview at a Glance
5. Plaque Psoriasis Disease Background and Overview
6. Plaque Psoriasis Patient Journey
7. Plaque Psoriasis Epidemiology and Patient Population
8. Plaque Psoriasis Treatment Algorithm, Current Treatment, and Medical Practices
9. Plaque Psoriasis Unmet Needs
10. Key Endpoints of Plaque Psoriasis Treatment
11. Plaque Psoriasis Marketed Products
12. Plaque Psoriasis Emerging Therapies
13. Plaque Psoriasis Seven Major Market Analysis
14. Attribute Analysis
15. Plaque Psoriasis Market Outlook (7 major markets)
16. Plaque Psoriasis Access and Reimbursement Overview
17. KOL Views on the Plaque Psoriasis Market.
18. Plaque Psoriasis Market Drivers
19. Plaque Psoriasis Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/plaque-psoriasis-market
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Wasting Syndrome Market
“Wasting Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Wasting Syndrome Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States